Format

Send to

Choose Destination
J Natl Cancer Inst. 2018 Oct 1;110(10):1123-1132. doi: 10.1093/jnci/djy033.

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.

Author information

1
Department of Molecular Medicine, Mayo Clinic, Rochester, MN.
2
Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
3
Department of Radiation Oncology, Mayo Clinic, Rochester, MN.
4
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
5
Division of Medical Oncology, Mayo Clinic, Rochester, MN.
6
Cancer Biology, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic, Rochester, MN.
7
Department of Neurological Surgery, Mayo Clinic, Rochester, MN.
8
Genome Analysis Core, Medical Genome Facility, Mayo Clinic, Rochester, MN.

Abstract

Background:

Attenuated measles virus (MV) strains are promising agents currently being tested against solid tumors or hematologic malignancies in ongoing phase I and II clinical trials; factors determining oncolytic virotherapy success remain poorly understood, however.

Methods:

We performed RNA sequencing and gene set enrichment analysis to identify pathways differentially activated in MV-resistant (n = 3) and -permissive (n = 2) tumors derived from resected human glioblastoma (GBM) specimens and propagated as xenografts (PDX). Using a unique gene signature we identified, we generated a diagonal linear discriminant analysis (DLDA) classification algorithm to predict MV responders and nonresponders, which was validated in additional randomly selected GBM and ovarian cancer PDX and 10 GBM patients treated with MV in a phase I trial. GBM PDX lines were also treated with the US Food and Drug Administration-approved JAK inhibitor, ruxolitinib, for 48 hours prior to MV infection and virus production, STAT1/3 signaling and interferon stimulated gene expression was assessed. All statistical tests were two-sided.

Results:

Constitutive interferon pathway activation, as reflected in the DLDA algorithm, was identified as the key determinant for MV replication, independent of virus receptor expression, in MV-permissive and -resistant GBM PDXs. Using these lines as the training data for the DLDA algorithm, we confirmed the accuracy of our algorithm in predicting MV response in randomly selected GBM PDX ovarian cancer PDXs. Using the DLDA prediction algorithm, we demonstrate that virus replication in patient tumors is inversely correlated with expression of this resistance gene signature (ρ = -0.717, P = .03). In vitro inhibition of the interferon response pathway with the JAK inhibitor ruxolitinib was able to overcome resistance and increase virus production (1000-fold, P = .03) in GBM PDX lines.

Conclusions:

These findings document a key mechanism of tumor resistance to oncolytic MV therapy and describe for the first time the development of a prediction algorithm to preselect for oncolytic treatment or combinatorial strategies.

PMID:
29788332
PMCID:
PMC6186520
DOI:
10.1093/jnci/djy033
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center